• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Thursday, November 19, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    FAA Administrator Takes Responsibility as Mullin Faces Tough Questions Over Nationwide Ground Stop

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Science

Alzheimer’s Drug with Modest Benefits Gets Green Light from FDA Advisers

by Theinsightpost
June 14, 2024
in Science
0 0
0
Alzheimer’s Drug with Modest Benefits Gets Green Light from FDA Advisers

Alzheimer’s Drug with Modest Benefits Gets Green Light from FDA Advisers

The drug donanemab slows progression of symptoms in people with early stages of Alzheimer’s disease, but questions linger about the durability of its effect

By Sara Reardon & Nature magazine

BSIP/UIG Via Getty Images

A drug for Alzheimer’s disease has won unanimous approval from independent scientists advising the US Food and Drug Administration (FDA), bringing the treatment a step closer to use in the clinic.

The drug, donanemab, would be the second on the US market to slow the cognitive decline caused by the disease. But donanemab’s effects are modest, it does not reverse symptoms and the FDA might limit who can take it.

At a 10 June meeting at the FDA’s headquarters in Silver Spring, Maryland, all 11 members of an FDA independent scientific advisory committee voted that donanemab, made by Eli Lilly, based in Indianapolis, Indiana, is effective at treating Alzheimer’s, at least in people in early stages of the disease, and that its benefits outweigh its risks.


On supporting science journalism

If you’re enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


That an advisory meeting was called at all came as a surprise to many observers, who had expected the FDA to quickly approve donanemab without convening an advisory committee. Instead, the FDA delayed its decision until after the public meeting could be held because of questions about the drug’s efficacy in people with certain markers of Alzheimer’s disease. But, in the end, “it was a very positive meeting”, says neurologist David Knopman at the Mayo Clinic in Rochester, Minnesota, who was not on the committee. “It would have been difficult for someone to object based on the standard of the data.”

Amyloid attacker

Donanemab is an antibody that attacks amyloid, a sticky protein that accumulates in the brains of people with Alzheimer’s disease. In data submitted to the FDA, Eli Lilly reported that the 622 trial participants who received donanemab and completed the trial lost their cognitive abilities more slowly over the study period than did those who received a placebo. However, the drug did not reverse the disease’s progression. Research1,2 shows that donanemab slows symptoms roughly as well as rival drug lecanemab, which also attacks amyloid. Lecanemab is made by the biopharmaceutical companies Eisai in Tokyo and Biogen in Cambridge, Massachusetts.

Unlike previous trials of monoclonal antibodies, Eli Lilly’s study tested only people whose brains contained both amyloid and another protein called tau that is associated with cognitive decline. Donanemab seemed to be more effective in people who had low to moderate tau levels at the start of the trial than in people who had high levels. But the FDA pointed out that the disease might have progressed more slowly in members of the lower-tau group than in those with higher tau levels.

At the meeting, advisory committee members were broadly supportive of the drug. However, some noted that Eli Lilly has little evidence that the drug works in people with no to very little tau. But the committee decided against restricting the drug’s usage on the basis of tau levels, because screening for tau is complex and costly. A screening requirement would prevent an unacceptably high number of people from accessing the drug, the committee decided.

The panel members also expressed concern about amyloid-related imaging abnormalities (ARIA), which are associated with brain bleeding and seizures that which can be fatal. ARIA is thought to occur when the antibodies weaken blood vessels in the brain. Eli Lilly recorded more ARIA-related deaths among people who received the drug than in the placebo group. Lecanemab has also been linked to ARIA, but the increased risk seems to be much higher with donanemab3.

Controversial therapies

The approval is a bright spot for amyloid-targeting Alzheimer’s drugs after numerous controversies. Despite the objections of its advisory committee, the FDA in 2021 approved the first such drug, aducanumab, another medication made by Biogen and Eisai, leading three committee members to resign in protest. A US Congressional investigation later found that that the FDA had improperly guided the manufacturers through the approval process. Many insurers were not convinced of the drug’s efficacy, and most refused to cover it. Biogen stopped making the drug earlier this year. And three people are thought to have died from ARIA-related conditions during clinical trials of lecanemab, sparking an outcry.

The committee convened to evaluate donanemab said that more research is still needed on the drug — for example, on how long people should take it for and its efficacy in people with different levels of tau. Knopman says that it remains to be seen whether the drug’s modest effect will persist for years.

The committee also recommended more research on the drug’s efficacy in people of colour — more than 90% of Eli Lilly’s trial participants were white. And they wanted to see more data on the drug in people who have Down’s syndrome, which raises the risk of Alzheimer’s, or genetic mutations that make them more prone to both Alzheimer’s, and ARIA. Committee member Kathleen Poston, a neurologist at Stanford University Medical Center in California, says scientists need to obtain these data “to make sure that these encouraging findings can be extrapolated to everyone with Alzheimer’s disease”. The FDA’s final decision is expected later this year.

This article is reproduced with permission and was first published on June 10, 2024.

ShareTweetSend
Previous Post

The European PM that could take Ursula von der Leyen’s job | World | News

Next Post

Group Stage – Hungary vs Switzerland – Sport Grill

Related News

Discover the Fascinating Secrets of NASA’s Voyager Mission: Test Your Knowledge!
Science

Discover the Fascinating Secrets of NASA’s Voyager Mission: Test Your Knowledge!

November 19, 2026
Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions
Science

Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions

November 18, 2026
Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance
Science

Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance

November 14, 2026
Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse
Science

Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse

November 12, 2026
Next Post
Group Stage – Hungary vs Switzerland – Sport Grill

Group Stage – Hungary vs Switzerland – Sport Grill

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      Anthropic Set to Make Market Debut Today Following Historic  Billion IPO

      Anthropic Set to Make Market Debut Today Following Historic $81 Billion IPO

      November 19, 2026
      Discover the Fascinating Secrets of NASA’s Voyager Mission: Test Your Knowledge!

      Discover the Fascinating Secrets of NASA’s Voyager Mission: Test Your Knowledge!

      November 19, 2026
      WNBA Begins Search for New Commissioner as Cathy Engelbert’s Tenure May Extend to 2027

      WNBA Begins Search for New Commissioner as Cathy Engelbert’s Tenure May Extend to 2027

      November 19, 2026
      Six Drainage Enhancement Projects Pending Financial Approval, Says Ahmed Ibrahim

      Six Drainage Enhancement Projects Pending Financial Approval, Says Ahmed Ibrahim

      November 19, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy